Guide · 7 min read
Tirzepatide vs. Semaglutide
Two of the most talked-about medications in a generation. Here's how they actually differ — and how to think about which one might fit you.
The short version
Semaglutide mimics one gut hormone (GLP-1). Tirzepatide mimics two (GLP-1 + GIP). In head-to-head evidence, tirzepatide tends to produce more weight loss on average, but semaglutide has a longer safety track record and more formulation options (including a daily pill).
Side-by-side
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Drug class | GLP-1 receptor agonist | GIP + GLP-1 dual agonist |
| FDA approvals | Type 2 diabetes (Ozempic/Rybelsus), chronic weight management (Wegovy) | Type 2 diabetes (Mounjaro), chronic weight management (Zepbound) |
| Dosing | Weekly injection or daily oral (Rybelsus) | Weekly injection |
| Typical top dose | 2.4 mg/week (Wegovy) | 15 mg/week (Zepbound) |
| Avg. weight loss at ~72 wks | ~15% (STEP trials) | ~21% (SURMOUNT-1) |
| Side effects | Nausea, constipation, fatigue, reflux | Similar profile — some patients tolerate it better |
| Cost (US, no insurance) | ~$1,000–$1,350/mo | ~$1,000–$1,300/mo |
How they work
Both slow gastric emptying, cue satiety in the brain, and blunt the "food noise" that makes constant snacking feel automatic. Tirzepatide adds GIP activity, which appears to enhance insulin response and, based on trial data, contributes to greater average weight loss.
Weight loss outcomes
The STEP trials of semaglutide (2.4 mg) showed roughly 15% average body-weight loss at 68 weeks. SURMOUNT-1, the pivotal trial of tirzepatide (15 mg), showed roughly 21% at 72 weeks. Real-world results vary widely — your ramp-up, adherence, sleep, protein intake, and activity all matter.
Side effects
The side effect profile is broadly similar — nausea, constipation, reflux, fatigue, occasional injection-site reactions. Some patients tolerate tirzepatide better despite the higher potency; others find semaglutide easier. There is no reliable way to predict this in advance. Both carry a boxed warning about thyroid C-cell tumors based on rodent studies.
Cost and access
US list prices are similar (~$1,000–$1,350/month). Coverage depends on your indication (diabetes vs. weight management) and your insurer. Compounded versions exist in a gray legal zone and quality varies — talk to your prescriber before going that route.
Which one should you take?
That's a conversation with your prescriber. What matters most for outcomes is not which molecule you pick — it's tolerating the ramp-up, staying on the medication long enough to see results, and pairing it with adequate protein and movement. Dosejoy is built to make that part easier, whichever medication you're on.
Track your journey in Dosejoy
Log doses, symptoms, and weight in one place. Get eating guidance tuned to your medication and week.
Start free →Not medical advice. Trial numbers are approximate and depend on dose, duration, and adherence. Always follow your prescriber.